SUMMARY -Th e purpose of this review is to present contemporary measures for preventing the increase in preovulatory progesterone (P) and its adverse eff ects on ovarian stimulation in in vitro fertilization (IVF). For the last 20 years, the increase of preovulatory P has been a topic of numerous discussions because its role is not fully understood in terms of its impact on pregnancy outcome after IVF. Some studies failed to establish a connection between the preovulatory P increase and successful IVF outcome regardless of the level of P, while, conversely, most other studies have reported on adverse eff ects of elevated P concentrations. Current strategies to prevent the increase in preovulatory P include an individualized approach with the use of mild stimulation protocols and early application of human chorionic gonadotropin for ovulation induction among good responders, delay in the transfer of fresh embryos from 3 rd to 5 th day, and cryopreservation of all embryos with the thawed embryo transfer in the natural cycle. Nevertheless, further studies are needed to confi rm the current preventive methods or enable the application of new strategies in order to lower or eliminate the detrimental eff ects of preovulatory P rise during ovarian stimulation in IVF.
Introduction
Elevated preovulatory serum progesterone (P) is frequently ascertained during the late follicular phase at the end of ovarian stimulation on the day of ovulation triggering with human chorionic gonadotropin (hCG) during the in vitro fertilization (IVF) cycle. Th e incidence of premature P rise varies widely from 13% to 71% depending on defi nition, cut-off level of P, stimulation protocols and population characteristics 1 .
Th e presence of premature luteinizing hormone (LH) surge during ovarian stimulation has been previously correlated with preovulatory P rise and it has been constantly associated with reduced pregnancy rates 2 . In order to prevent premature LH rise and consequently premature P rise, gonadotropin-releasing hormone (GnRH) analogues have been introduced. Although the signifi cance of GnRH analogues in the prevention of preovulatory P rise has been proven, higher P levels have been recorded in approximately 35% of GnRH agonist cycles and 38% of GnRH antagonist cycles 3 . Th e ovarian response to follicle stimulating hormone (FSH) in recombinant (rec)-FSH/GnRH antagonist cycles has been associated with the risk of P elevation. Furthermore, a direct correlation between premature P rise and estradiol (E2) levels and the number of follicles on the day of hCG administration has been widely confi rmed. Th e association between the high E2 and premature P elevation could be explained by an excess of proliferating granulosa cells that can lead to an increased P production 4 . According to the two-cell, two-gonadotropin theory and the fact that excessive FSH stimulation may increase the production of P, the inclusion of LH activity products in stimulation protocols to counterbalance the eff ect of FSH may help reduce the risk of late follicular P increases 5 . However, a systematic review of several studies comparing FSH administration alone or in combination with LH activity products could not demonstrate any signifi cant eff ect of 'LH activity' on serum preovulatory P elevation. Th erefore, the major determining factor for the risk of P rise at the time of hCG administration remains the degree of ovarian response to FSH 6 . However, early addition of increasing doses of hCG (0, 50, 100 and 150 IU) from the beginning of ovarian stimulation in combination with rec FSH + GnRH antagonist was associated with an increased risk of P elevation 7 . Furthermore, it appears that the choice of GnRH analogue has an impact on the risk of P elevation because preovulatory P levels were higher in women treated with GnRH agonist as compared with GnRH antagonist. Th ese diff erences can be explained by stronger ovarian response to FSH as the main driver of P output and by higher endogenous LH concentration during the last few days of stimulation in favor of GnRH agonist 8, 9 . It appears that endogenous LH in the late follicular phase acts positively on P secretion and women treated with GnRH agonist protocols are more prone to P elevation 10 . Since the early 1990s, there has been an ongoing debate in more than 60 studies in women undergoing ovarian stimulation with controversial conclusions regarding the impact of preovulatory P on IVF outcome. Several previous and recent studies failed to demonstrate any negative eff ect of P rise [10] [11] [12] . Th e fi rst metaanalysis of 12 studies, published in 2007, has reported that there was a nonsignifi cant negative association between P elevation and pregnancy rate in women with GnRH analogues and gonadotropins 12 . However, the second meta-analysis from 2012 focused on women using GnRH antagonists and gonadotropins (fi ve studies) states that P elevation on the day of hCG administration is associated with a signifi cantly decreased probability of clinical pregnancy per cycle 13 . Similarly, in the third meta-analysis from 2013 of over 60 000 fresh IVF cycles it was found that P elevation on the day of hCG was associated with a signifi cantly decreased probability of pregnancy in women, whatever the GnRH analogue used. Th e thresholds of serum P on the day of hCG administration were arbitrarily chosen from 0.4 ng/mL to 3 ng/mL and the strongest eff ect size of P elevation for achievement of pregnancy was observed with P thresholds between 1.5 ng/mL and 1.75 ng/mL 14 . Several recent studies also established that P elevation on the day of hCG administration could be associated with a risk of reduced implantation rate. Despite the use of diff erent thresholds of serum P, the optimal P threshold over which a detrimental eff ect on IVF outcome might be observed has been estimated to 1.5 ng/mL and this threshold has been commonly used 10, 15, 16 . It seems that the P threshold in women using GnRH agonists is dependent on the degree of the ovarian response because in poor responders, the P threshold associated with a lower pregnancy rate was estimated at 1.5 ng/mL, in patients with normal ovarian response 1.75 ng/mL and in high responders 2.25 ng/mL 17 . Consequently, in patients treated with rec FSH and GnRH antagonists, P elevation does not compromise pregnancy rates in high responders, although its incidence increases with ovarian response and elevated P at a threshold of 1.5 ng/mL is independently associated with a decreased chance of pregnancy in low-to-normal responders. Th erefore, it seems that the detrimental eff ect of P elevation on the implantation rate could be compensated for by an increased yield of high-quality oocytes 18 . Interestingly, the duration of P elevation could have a stronger impact on cycle outcome than the absolute serum P concentration on the day of hCG. Th e clinical pregnancy rate is signifi cantly inversely correlated with the duration of premature serum P elevation above the cut-off value of 1.0 ng/mL, whatever the protocol used and the intensity of the ovarian response 19 . It seems that the use of a multivariable analysis is the proper way of assessing the adverse eff ect of preovulatory P elevation on live birth rates, when compared with the bivariate analysis that was used in most of the studies that failed to identify the detrimental eff ect in fresh IVF cycles 20 . Since preovulatory P rise during ovarian stimulation is not associated with any signifi cant changes in either oocyte or embryo quality, it is now convincingly accepted that P prematurely opens the window of implantation and modifi es endometrial receptivity, leading to defective implantation and mainly contributing to the decreased pregnancy rate 14 . Indeed, any 3-day advancement in endometrial receptivity assessed by endometrial biopsy at the time of oocyte retrieval results in a signifi cant decrease in implantation rate, presumably related to P elevation 21, 22 . However, direct evidence for an eff ect of P rise on the endometrium has been provided by the altered gene expression profi le in a recent functional genomics analysis 23, 24 . Since the majority of published studies demonstrated a detrimental eff ect of preovulatory P elevation which contributes to a decreased pregnancy rate, the purpose of this review is to analyze current preventive strategies that may improve pregnancy outcome following IVF.
Prevention of Preovulatory Progesterone Elevation
Mild ovarian stimulation protocols are associated with lower E2 levels and therefore may be useful in the prevention of premature P rise due to strong correlation between ovarian response and preovulatory P rise 25 , which may be achieved with limited gonadotropins or with alternatives such as anti-estrogens or aromatase inhibitors since they reduce the dose of gonadotropins required for stimulation and keep estrogen levels low 26 . Th ere are limited clinical data available concerning the use of aromatase inhibitors in IVF treatment. Up to date, only three randomized controlled trials involving a total of 80 women studied the use of aromatase inhibitors in IVF 27 . However, new studies yielded promising results on the benefi t of aromatase inhibitor use in terms of ovarian stimulation for IVF 28, 29 . Although mild stimulation is correlated with a reduced risk of premature P rise, lower pregnancy rates per cycle, fewer embryos for cryopreservation and still not available individualized FSH-dosing algorithms have been reported 27 . Moreover, it is important to consider each patient's general condition including age, ovarian reserve, embryo grading and the capacity of frozen/thawed embryo transfer when mild protocols are used for stimulation 30 . An earlier hCG trigger, when follicles reach a diameter of 15-16 mm, has been suggested as a strategy for preventing premature P rise. It has been suggested that earlier hCG trigger should take place when ≥3 follicles of ≥16 mm diameter are present on ultrasonography 31 . However, this early trigger has been associated only with lower preovulatory P but not with better ongoing pregnancy rates 32 . In order to avoid premature P rise and its detrimental eff ect on IVF outcome, earlier trigger in high responders is more suitable as compared with normal and poor responders 31, 33 . Due to the potential predictive role of E2 concentrations for premature P rise, fi nal oocyte maturation can be triggered when the E2 concentration reaches the point of having a risk of preovulatory P rise 34 . One of the strategies that have been suggested to overcome the detrimental eff ect of advanced endometrial maturation is to enable endometrial recovery before transfer. Numerous studies investigated the benefi t of day 5 compared to day 3 embryo transfer (ET) [35] [36] [37] ; increased probability of pregnancy with day 5 ET was recorded in 2 independent trials 36, 38 . In other words, a higher rate of early pregnancy loss was recorded after day 3 single ET as compared with day 5 single blastocyst transfer in GnRH antagonist stimulated IVF cycles. Two diff erent systematic reviews and meta-analysis independently confi rmed previous fi ndings; improved IVF outcome was associated with day 5 ET and not with day 3 ET 38,39 . Analyzing both developmental stage and fragmentation rate, the implantation potential of advanced blastocysts was infl uenced by developmental stage on day 5 and fragmentation rate on day 3 ET 40 . Lower implantation rate on day 3 ET is most likely associated with disturbed embryoendometrium synchrony in terms of high preovulatory P. Furthermore, as the endometrium seems to be recovered from the supraphysiological P values on day 5, a better implantation rate is quite expected with day 5 single blastocyst transfer 41 . However, only a few studies failed to confi rm the preference of day 5 ET as a potential strategy to overcome the deleterious eff ect of elevated P on IVF pregnancy outcome. Th erefore, better embryo implantation and live birth rate could not be confi rmed on day 5 fresh ET in terms of the rise of serum P levels ≥2.0 ng/mL on the day of hCG administration in cycles with GnRH agonists 42 . Similarly, a study from 2013 failed to demonstrate the preference of day 5 ET as a strategy to overcome the detrimental eff ect of P rise on IVF pregnancy outcome 33 . Nevertheless, as the majority of studies yielded better implantation rate and IVF pregnancy outcome with day 5 single blastocyst transfer as compared with day 3 single ET, the selection of blastocyst transfer as a strategy for overcoming the adverse eff ect of high preovulatory P seems to be quite justifi ed 36, 37, 41 . Elective cryopreservation of all embryos with subsequent transfer in a natural cycle or during ovulation induction has been proposed as a solution to avoid the negative eff ect of high preovulatory P on IVF outcome, as well as in the prevention of ovarian hyperstimulation syndrome 42, 43 . Indeed, various studies yielded signifi cantly higher ongoing and clinical pregnancy rates when frozen ET was used as compared with fresh ET [44] [45] [46] . It seems that the adverse eff ect of P elevation on endometrium in terms of IVF outcome could be overcome by frozen-thawed embryo transfer (FET) in a later non-stimulated cycle, since the embryo-endometrium synchrony is thus re-established, although poor quality embryos could not be eliminated through the utilization of cryopreservation 46 . In the past decade, the number of frozen-thawed embryo transfer cycles per started IVF cycle has increased steadily and at the same time the percentage of frozen-thawed embryo transfers that resulted in live births has increased. Currently, cryopreservation of human embryos is more important than ever for the cumulative pregnancy rate after IVF. It seems that freeze-all strategy, in which all embryos are frozen and no fresh transfer is conducted, has been proven to increase success rates in IVF cycles 47 .
Conclusion
Current strategies in the prevention of preovulatory P rise include an individualized approach with the use of mild stimulation protocols with intensive monitoring of folliculogenesis and earlier use of hCG for ovulation induction in high responders. However, to avoid the negative endometrial eff ects of P rise, it should be useful to delay ET from day 3 to day 5. Finally, the most appropriate choice would be to cancel fresh ET and freeze all embryos with FET in the natural cycle. However, there is the need for further research which would confi rm the current preventive methods or enable the application of new strategies in order to lower or eliminate the detrimental eff ects of preovulatory P rise during ovarian stimulation in IVF procedure. Svrha ovoga preglednog članka je prikazati suvremene mjere za prevenciju porasta predovulacijskog progesterona (P) i njegovih nepovoljnih učinaka kod stimulacije jajnika u postupku izvantjelesne oplodnje. Unatrag 20-ak godina porast predovulacijskog P tema je brojnih rasprava, jer njegova uloga nije u potpunosti razjašnjena u pogledu utjecaja na ishod trudnoće nakon postupka izvantjelesne oplodnje. Neka istraživanja nisu utvrdila nikakvu povezanost između porasta predovulacijskog P u odnosu na uspješnost postupka izvantjelesne oplodnje neovisno o razini P, dok nasuprot tome, većina drugih istraživanja izvješćuje o nepovoljnim učincima povišene koncentracije P. Suvremene strategije u prevenciji porasta predovulacijskog P uključuju individualizirani pristup primjenom blažih stimulacijskih protokola te raniju primjenu humanog korionskog gonadotropina za indukciju ovulacije kod bolesnica koje dobro reagiraju na stimulaciju, odgodu prijenosa svježih zametaka s 3. na 5. dan i krioprezervaciju svih zametaka uz transfer odmrznutih embrija u prirodnom ciklusu. Neophodna su daljnja istraži-vanja koja će potvrditi postojeće prevencijske metode ili omogućiti primjenu novih strategija, sa svrhom onemogućavanja nepovoljnog utjecaja porasta predovulacijskog P na ishod trudnoće nakon postupka izvantjelesne oplodnje.
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